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geometric least squares (LS) means (with ramucirumab vs. 
alone) of 1.09 (90 % confidence interval [CI] 0.93, 1.29) 
for AUC(0–∞) and 0.97 (90 % CI 0.83, 1.13) for Cmax. In 
addition, similar ramucirumab pharmacokinetic character-
istics were observed with or without paclitaxel administra-
tion. The ratios of geometric LS means of AUC(0–∞) and 
Cmax of ramucirumab (with paclitaxel vs. alone) were 1.00 
(90 % CI 0.84, 1.19) for AUC(0–∞) and 1.07 (90 % CI 0.93, 
1.24) for Cmax, respectively.
Conclusions Concomitant paclitaxel administration is 
unlikely to affect the pharmacokinetics of ramucirumab, 
and vice versa. The incidence and severity of adverse 
events were consistent with the known safety profiles of 
paclitaxel and ramucirumab.
Keywords Ramucirumab · Paclitaxel · Pharmacokinetics · 
Drug–drug interactions · Cancer
Introduction
Pathways that mediate angiogenesis are considered impor-
tant targets in cancer drug development. Vascular endothe-
lial growth factors (VEGFs) have emerged as key regula-
tors of angiogenesis. VEGF receptor 2 (VEGFR-2) is the 
primary mediator of proangiogenic effects of VEGF-A, 
and experimental evidence suggests that the VEGF-A/
VEGFR-2 interaction plays an important role in tumor 
angiogenesis, a process essential for tumor growth and 
metastasis [1, 2]. Disruption of the interaction between 
VEGF-A and VEGFR-2 has proven to have therapeutic 
application in the treatment of cancer.
Ramucirumab is a recombinant human immunoglobu-
lin G1 monoclonal antibody that specifically binds to the 
VEGFR-2 receptor with high affinity, preventing binding 
Abstract 
Purpose The objective of this phase II study was to evalu-
ate pharmacokinetic interaction potential between ramu-
cirumab and paclitaxel in patients with advanced cancer.
Methods This study was designed to assess 2-way phar-
macokinetic drug–drug interactions between ramucirumab 
and paclitaxel. Twenty-four patients participated in Part A, 
which consisted of a 2-week monotherapy period in which 
paclitaxel 80 mg/m2 was administered on day 1, followed 
by a 4-week cycle of combination treatment with ramu-
cirumab (8 mg/kg on days 1 and 15; paclitaxel on days 1, 
8, and 15). Patients could continue to receive combination 
therapy with ramucirumab and paclitaxel. In 16 patients in 
Part B, ramucirumab monotherapy was administered on 
day 1 of a 3-week cycle. Patients could continue to receive 
ramucirumab monotherapy or combination therapy with 
paclitaxel.
Results Concomitant administration of ramucirumab had 
no effect on pharmacokinetics of paclitaxel, with ratios of 
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of VEGF-A, VEGF-C, and VEGF-D and inhibiting recep-
tor activation [3, 4]. In patients with previously treated 
advanced gastric or gastroesophageal junction adenocarci-
noma, the results from 2 randomized, phase III trials dem-
onstrated that overall survival was significantly increased in 
patients who received ramucirumab as monotherapy (haz-
ard ratio [HR] 0.78; 95 % confidence interval [CI] 0.60, 
0.998; P = 0.047) and in combination with paclitaxel (HR 
0.81; 95 % CI 0.68, 0.96; P = 0.017) [5, 6]. These trials 
led to approval of ramucirumab as second-line therapy for 
advanced gastric cancer.
Paclitaxel is a cytotoxic agent active against various types 
of malignancies and is used as a single agent or in combi-
nation with other agents for advanced gastric cancer [7, 8]. 
Paclitaxel is a microtubule inhibitor and is metabolized by 
cytochromes P450 (CYP) CYP3A4 and CYP2C8 [9, 10].
An increase in chemotherapy-associated toxicities such 
as neutropenia has been observed with the addition of 
anti-VEGF antibodies [11]. In ECOG 4599, a randomized 
phase III trial in non-squamous non-small cell lung cancer 
(NSCLC), patients received paclitaxel/carboplatin with or 
without bevacizumab [12]. In this trial, the rates (grade ≥4 
hematologic; grade ≥3 non-hematologic) of hypertension, 
proteinuria, bleeding, neutropenia, febrile neutropenia, and 
thrombocytopenia were significantly higher in the paclitaxel/
carboplatin/bevacizumab group than in the paclitaxel/carbo-
platin group (P < 0.05). The underlying mechanism of these 
events is unknown. An argument could be made whether 
the pharmacokinetics of chemotherapy can be impacted by 
coadministration with anti-angiogenic compounds.
To support the concomitant use of ramucirumab with 
paclitaxel for the treatment of advanced gastric cancer, 
this phase II study assessed the potential for pharmacoki-
netic drug–drug interactions (DDIs) between ramucirumab 
and paclitaxel when given in combination in patients with 
advanced malignant solid tumors.
Methods
Patients
This study was a 2-part, multicenter, open-label phase II 
study in patients with advanced solid tumors (ClinicalTri-
als.gov: NCT01515306). Eligible patients were 18 years 
of age or older; had metastatic or locally advanced malig-
nant solid tumors that were resistant to standard therapy 
or for which no standard therapy was available; had ade-
quate organ and hematologic function; had no history of 
uncontrolled hypertension or bleeding; and had an ECOG 
PS of 0–2. For Part A only, patients were required to have 
had 1 or fewer prior taxane-containing treatment regimens 
(including taxane monotherapy), which should have been 
completed at least 6 months before the first dose of study 
drug. Prior treatment with bevacizumab was allowed. For 
Part B only, prior bevacizumab and taxane-containing 
treatment regimens (including taxane monotherapy) were 
allowed and should have been completed at least 6 months 
before the first dose of study drug. The study was under-
taken in accordance with principles of the Declaration of 
Helsinki and Good Clinical Practice guidelines and with 
local institutional review board approval. Written informed 
consent was obtained from all participants.
Treatment
This study was designed to assess 2-way pharmacokinetic 
DDIs between ramucirumab and paclitaxel.
Part A consisted of a 2-week monotherapy period (Cycle 
1), during which paclitaxel 80 mg/m2 was administered on 
day 1, followed by a 4-week cycle of combination treat-
ment (Cycle 2). Ramucirumab (8 mg/kg) was administered 
on days 1 and 15, and paclitaxel (80 mg/m2) was adminis-
tered on days 1, 8, and 15 of each 4-week treatment cycle. 
This was followed by continuation of the treatment phase 
(Cycle 3 and beyond), in which patients could continue 
to receive combination therapy with ramucirumab and 
paclitaxel.
In Part B, ramucirumab 8 mg/kg monotherapy was 
administered on day 1 of a 3-week cycle. This was fol-
lowed by continuation of the treatment phase (Cycle 2 and 
beyond), in which patients could continue to receive ramu-
cirumab 8 mg/kg monotherapy or combination therapy 
with paclitaxel.
All patients who completed Cycle 1, Day 1 and Cycle 2, 
Day 1 in Part A and Cycle 1, Day 1 in Part B were included 
in the DDI analysis.
Pharmacokinetics
In Part A, on Day 1 of Cycle 1, blood samples for paclitaxel 
concentration analysis were drawn at time point 0 (immedi-
ately before initiation of paclitaxel infusion) and at 1, 1.5, 
2, 5, 7, 24, 48, 72, and 168 h after the start of the paclitaxel 
infusion. For Cycle 2, blood samples for paclitaxel and 
ramucirumab concentration analysis were drawn at day 1, 
time point 0 (immediately before initiation of ramucirumab 
infusion) and at 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, and 
336 h after the start of the ramucirumab infusion.
In Part B, on Day 1 of Cycle 1, blood samples for ramu-
cirumab concentration analysis were drawn at time point 
0 (immediately before initiation of ramucirumab infusion) 
and at 1, 1.5, 2, 5, 7, 24, 48, 72, 168, 264, 336, 408, and 
504 h after the start of the ramucirumab infusion.
Plasma samples were analyzed for paclitaxel using a val-
idated liquid chromatography tandem mass spectrometry 
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method (PPD method LCMSC 163.4 version 1.00) at PPD 
(Richmond, VA, USA). Serum samples were analyzed for 
ramucirumab using a modified validated enzyme-linked 
immunosorbent assay (ELISA) method at Intertek Pharma-
ceutical Services (San Diego, California, USA).
Pharmacokinetic parameters were assessed for ramu-
cirumab and paclitaxel and were calculated by standard 
non-compartmental methods of analysis using Phoenix® 
WinNonlin® Professional 6.2. Area under the curve versus 
time curve from t = 0 extrapolated to infinity (AUC(0–∞)) 
and Cmax was dose normalized for the DDI comparisons 
because patients received different absolute doses.
Statistical analyses
Log-transformed pharmacokinetic parameters of AUC(0–∞) 
and Cmax for paclitaxel were analyzed via a linear mixed-
effects model containing treatment (paclitaxel; ramu-
cirumab plus paclitaxel) as a fixed effect and patient as a 
random effect in Part A.
LS means and 90 % CIs for the differences between 
AUC(0–∞) and Cmax of paclitaxel in log scale between Cycle 
1 and 2 were estimated before transformation back to the 
original scale to estimate the ratio of geometric means and 
90 % CIs for the comparisons (ramucirumab plus paclitaxel 
vs. paclitaxel).
A 2-sample t test was used to analyze the log-trans-
formed pharmacokinetic parameters of AUC(0–∞) and Cmax 
for ramucirumab when coadministered with paclitaxel (Part 
A) and for ramucirumab monotherapy (Part B).
All calculations were performed using SAS® version 9.2.
Safety
All patients receiving at least one dose of a study drug were 
included in the summary and analysis of safety in Parts A 
and B of the study. All enrolled patients were assessed for 
toxicity before each infusion using National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(NCI-CTCAE) v. 4.0.
Results
Patient demographics and disease characteristics
Part A
Twenty-four patients (11 males [45.8 %] and 13 females 
[54.2 %]) between the ages of 23 and 83 years (median age 
60.5 years) participated in Part A of this study (Table 1). 
The majority of patients had an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) of 0 or 1 (20 
patients, 83.3 %). Four patients (16.7 %) had an ECOG PS 
of 2. Breast carcinoma (4 patients, 16.7 %) followed by 
NSCLC, soft tissue sarcoma, and urothelial carcinoma (3 
patients each, 12.5 %) were the most commonly reported 
sites of origin for the primary tumor.
Part B
Part B comprised 16 patients (7 males [43.8 %] and 9 
females [56.3 %]) between the ages of 19 and 83 years 
Table 1  Patient demographics and disease characteristics
ECOG PS Eastern Cooperative Oncology Group performance status
a Part A, one patient each (4.2 %): colorectal, gastric, melanoma, 
mesothelioma, neuroendocrine tumor, ovarian, cholangiocarcinoma, 
chondrosarcoma, leiomyosarcoma, squamous cell carcinoma of the 
tonsil, unknown primary site. Part B, one patient each (6.3 %): meso-
thelioma, neuroendocrine tumor, pancreatic, small cell lung, urothe-
lial, extrapulmonary small cell, large cell neuroendocrine tumor of 






 Male 11 (46) 7 (44)
 Female 13 (54) 9 (56)
Age, years
 Median, (range) 60.5 (23–83) 61.0 (19–83)
 <65, n (%) 14 (58) 10 (63)
 ≥65, n (%) 10 (42) 6 (38)
Race, n (%)
 Asian 1 (4) 1 (6)
 White 22 (92) 15 (94)
 Multiple 1 (4) 0
Ethnicity, n (%)
 Hispanic or Latino 1 (4) 0
 Non-Hispanic or Latino 23 (96) 16 (100)
ECOG PS, n (%)
 0 6 (25) 9 (56)
 1 14 (58) 6 (38)
 2 4 (17) 1 (6)
Duration of disease, months
 Median (range) 35 (3–174) 17 (2–64)
Prior (21 days) anticancer treatment, 
n (%)
1 (4) 0
Prior (14 days) radiotherapy, n (%) 3 (13) 0
Prior taxane therapy, n (%) 2 (8) 0
Type of cancer,a n (%)
 Breast 4 (17) 0
 Non-small cell lung 3 (13) 2 (13)
 Sarcoma, soft tissue 3 (13) 4 (25)
 Urothelial 3 (13) 0
 Hepatobiliary 0 2 (13)
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(median age 61.0 years). The majority of patients in Part B 
had an ECOG PS of 0 or 1 (15 patients, 93.8 %). Only one 
patient (6.3 %) had an ECOG PS of 2. Soft tissue sarcoma 
(4 patients, 25.0 %) followed by hepatobiliary carcinoma 
and NSCLC (2 patients each, 12.5 %) were the most com-
monly reported sites of origin for the primary tumor.
Pharmacokinetic analysis
Concentrations of paclitaxel and ramucirumab were deter-
mined in 23 patients in Part A and 16 patients in Part B. No 
pharmacokinetic parameters were calculated for one patient in 
Part A because of an infusion duration of approximately 4 h.
Paclitaxel pharmacokinetics
Figure 1a shows mean plasma concentrations of paclitaxel 
over time after monotherapy (Part A, Cycle 1) and com-
bination therapy (Part A, Cycle 2). Overlapped paclitaxel 
pharmacokinetic profiles were observed between mono-
therapy and combination therapy. Maximum paclitaxel 
plasma concentrations were achieved at the end of pacli-
taxel infusion and then declined in a biexponential fashion, 
consistent with previously reported profiles [13, 14]. Statis-
tical analysis demonstrated that coadministration of ramu-
cirumab had no effect on dose-normalized area under the 
curve (AUC(0–∞)) and maximum drug concentration (Cmax) 
Fig. 1  Mean (±SD) plasma 
concentration–time profile of 
paclitaxel from Part A, Cycle 
1 (monotherapy) and Cycle 2 
(combination therapy); inset: 
concentration curve from 0 to 
9 h (a). Mean (±SD) serum 
concentration–time profile of 
ramucirumab from Part A, cycle 
2 (combination therapy), and 
Part B, cycle 1 (monotherapy); 
inset: concentration curve from 
0 to 25 h (b). H hour, SD stand-
ard deviation
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of paclitaxel; ratios (Part A, Cycle 2 vs. Cycle 1) of geo-
metric least squares (LS) means were 1.09 (90 % CI 0.93, 
1.29) and 0.97 (90 % CI 0.83, 1.13), respectively (Table 2). 
Other pharmacokinetic parameters were also similar 
between paclitaxel monotherapy and in combination with 
ramucirumab (Table 3).
Ramucirumab pharmacokinetics
As shown in Fig. 1b, mean serum concentrations of ramu-
cirumab over time in combination with paclitaxel (Part A, 
Cycle 2) and as monotherapy (Part B, Cycle 1) were simi-
lar. Ramucirumab pharmacokinetic parameters between 
monotherapy and in combination with paclitaxel were also 
comparable (Table 4). Statistical analysis was performed 
to assess the effect of coadministration of paclitaxel on 
the pharmacokinetics of ramucirumab. Dose-normalized 
AUC(0–∞) and Cmax of ramucirumab in Cycle 2 of Part A 
were similar to those when ramucirumab was administered 
alone in Cycle 1 of Part B, with ratios (Part A, Cycle 2 vs. 
Part B, Cycle 1) of geometric means of 1.00 (90 % CI 0.84, 




In Part A, paclitaxel was administered in Cycle 1 (n = 24), 
and ramucirumab plus paclitaxel was administered in 
Table 2  Drug–drug interaction assessment
AUC(0–∞) area under the plasma concentration versus time curve from time zero extrapolated to infinity, CI confidence interval, Cmax maximum 
plasma drug concentration, LSM least squares mean, n number of patients included in the analysis, PK pharmacokinetics
a For the population of patients who completed Cycle 1, Day 1 and Cycle 2, Day 1




Ratio of geometric LSM
(90 % CI)
The effect of coadministration of 
ramucirumab on paclitaxel
Paclitaxel alone cycle 1 Part A Ramucirumab+ paclitaxel 
cycle 2 Part A
Ramucirumab+ paclitaxel: 
paclitaxel
AUC(0-∞) (ng h/mL/mg) 19 29.00 (24.50, 34.34) 17 31.67 (26.58, 37.73) 1.09 (0.93, 1.29)
Cmax (ng/mL/mg) 21 18.84 (16.03, 22.13) 20 18.30 (15.54, 21.56) 0.97 (0.83, 1.13)
The effect of coadministration of 
paclitaxel on ramucirumab
Ramucirumab alone cycle 1 
Part B
Ramucirumab+ paclitaxel 
cycle 2 Part A
Ramucirumab+ paclitaxel: 
ramucirumab
AUC(0–∞) (ng h/mL/mg) 15 55.32 (48.97, 62.50) 13 55.43 (48.63, 63.18) 1.00 (0.84, 1.19)
Cmax (ng/mL/mg) 16 0.36 (0.33, 0.39) 21 0.38 (0.34, 0.43) 1.07 (0.93, 1.24)
Table 3  Paclitaxel pharmacokinetic parameters as monotherapy or as combination therapy
AUC(0–∞) area under the plasma concentration versus time curve from time zero extrapolated to infinity, Cmax maximum plasma drug concentra-
tion, CL clearance, CV% percentage coefficient of variation, n number of subjects who had data for calculation of at least one pharmacokinetic 
parameter, t1/2 terminal half-life, Vss volume of distribution at steady state following intravenous administration
a 21 subjects completed Cycle 2, Day 1, but no pharmacokinetic parameters were calculated for one patient because of an infusion duration of 
4.32 h
b Geometric mean (range)
c n = 21
d n = 17
Parameter Geometric mean (CV%)
Paclitaxel alone (cycle 1)
(n = 23)
Paclitaxel + ramucirumab (cycle 2)
(n = 20a)
Cmax (ng/mL) 2742.61 (30) 2662.40 (47)
Dose-normalized Cmax (ng/mL/mg) 19.1 (33) 18.5 (54)
tb1/2 (h) 11.4
c (8.26–18.9) 11.4d (6.97–15.6)
AUC(0–∞) (ng h/mL) 4280
c (29) 4560d (46)
Dose-normalized AUC(0–∞) (ng h/mL/mg) 29.7
c (36) 31.4d (52)
CL (L/h) 33.7c (36) 31.9d (52)
Vss (L) 241
c (35) 226d (72)
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Cycle 2 + (n = 21). In Cycle 1, 2 patients (8.3 %) discon-
tinued due to a treatment-emergent adverse event (TEAE): 
1 patient discontinued due to grade 3 increased hepatic 
enzymes, and 1 patient discontinued due to a grade 2 
infusion-related reaction. Two patients (8.3 %) had a 
reduced or interrupted dose in Cycle 1 due to neutrope-
nia and infusion-related reaction. In Cycle 2 or beyond, 1 
(4.8 %) patient discontinued study treatment due to grade 
3 anemia. In the safety population in Part A, 10 patients 
(41.7 %) had a TEAE leading to dose reduction or inter-
ruption, 7 (29.2 %) of which were grade 3. Reasons for 
dose modifications included grade 3 neutropenia, pares-
thesia, hypophosphatemia, influenza and grade 2 neutro-
penia and infusion-related reaction. TEAEs occurring in 
at least 10 % of patients are summarized in Table 5. Over-
all, the most frequent any grade TEAEs were fatigue (12 
patients, 50.0 %), anemia (10 patients, 41.7 %), and diar-
rhea, decreased appetite, and epistaxis (7 patients each, 
29.2 %).
In Part A, adverse events of special interest (AESI) for 
patients who received ramucirumab in Cycle 2 and beyond 
included 8 patients (38.1 %) who experienced bleed-
ing/hemorrhagic events, including epistaxis (7 patients, 
33.3 %) and hemoptysis in 2 patients (9.5 %), 1 with colo-
rectal cancer, and 1 with ovarian cancer. None of these 
events were grade 3 or greater. Five patients (23.8 %) expe-
rienced hypertension. Of these, 2 patients (9.5 %) expe-
rienced grade 3 hypertension; 1 of these 2 patients had a 
prior history of hypertension. One patient (4.8 %) experi-
enced grade 3 pulmonary embolism.
Five of 24 patients (20.8 %) experienced serious adverse 
events (SAEs) during Part A. Of these, 3 patients (12.5 %) 
experienced SAEs that were considered related to study 
treatment. Three patients (12.5 %) died due to progressive 
disease, and 1 patient (4.2 %) died during Cycle 1 in Part A 
due to an AE that was not considered related to study treat-
ment but to underlying disease progression.
Part B
Sixteen patients in Part B received ramucirumab monother-
apy in Cycle 1; patients were allowed to continue to receive 
ramucirumab alone or in combination with paclitaxel. 
No patient discontinued from the study due to TEAEs in 
Cycle 1. One patient experienced an AE, leading to dose 
reduction or interruption in Cycle 2 + due to an infusion-
related reaction. The most frequent any grade TEAEs 
were epistaxis (4 patients, 25.0 %) and nausea (3 patients, 
18.8 %; Table 5). Six patients (37.5 %) experienced AESIs 
in Part B. Four patients (25.0 %) experienced bleeding/
hemorrhagic events (epistaxis). One patient each (6.3 %) 
experienced mild proteinuria and increased blood creati-
nine levels. None of these events were grade 3 or greater. 
No SAEs or deaths occurred in Part B.
Discussion
The primary objective of this phase II trial was to evaluate 
potential pharmacokinetic DDIs between ramucirumab and 
paclitaxel in patients with advanced malignant solid tumors 
resistant to standard therapy or for whom standard therapy 
was no longer available. The results demonstrated that no 
clinically meaningful changes in paclitaxel or ramucirumab 
Table 4  Ramucirumab pharmacokinetic parameters as combination therapy or as monotherapy
AUC(0–∞) area under the plasma concentration versus time curve from time zero extrapolated to infinity, Cmax maximum plasma drug concentra-
tion, CL clearance, CV % percentage coefficient of variation, n number of subjects who had data for calculation of at least one pharmacokinetic 
parameter, t1/2 terminal half-life, Vss volume of distribution at steady state following intravenous administration
a Geometric mean (range)
b n = 13
c n = 15
Parameter Geometric mean (CV%)
Part A Part B
Paclitaxel + ramucirumab (cycle 2)
(n = 21)
Ramucirumab alone (cycle 1)
(n = 16)
Cmax (μg/mL) 216.41 (24) 205.71 (14)
Dose-normalized Cmax (μg/mL/mg) 0.384 (31) 0.358 (18)
ta1/2 (h) 139
b (78.5–193) 157c (77.9–241)
AUC(0–∞) (μg h/mL) 29100
b (28) 32100c (29)
Dose-normalized AUC(0–∞) (μg h/mL/mg) 55.4
b (27) 55.3c (27)
CL (L/h) 0.018b (27) 0.018c (27)
Vss (L) 3.41
b (23) 3.95c (23)
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exposure were observed when ramucirumab 8 mg/kg and 
paclitaxel 80 mg/m2 were coadministered in patients with 
solid tumors.
As paclitaxel is mainly metabolized by hepatic 
cytochrome P450 enzymes and monoclonal antibodies are 
eliminated through Fc receptor-mediated immunoglobulin 
clearance mechanisms and specific target-mediated drug 
disposition pathways, this finding was not unexpected [10, 
15]. In DDI studies with other biologics, similar results 
were shown. A phase II study evaluating pharmacokinet-
ics and safety found that the combination of paclitaxel 
and trastuzumab was generally well tolerated, with no 
unexpected toxicities and no pharmacokinetic interactions 
in women with human epidermal growth factor receptor 
2-overexpressing metastatic breast cancer [16]. Likewise, 
no pharmacokinetic interactions were found with cetuxi-
mab in combination with paclitaxel and carboplatin, and 
the combination was safe and well tolerated in a population 
of stage IV NSCLC patients [17].
Systemic taxane-based chemotherapy is commonly used 
for patients with advanced disease. In a pivotal phase III 
study (RAINBOW), ramucirumab demonstrated signifi-
cant improvement in overall survival in combination with 
paclitaxel versus paclitaxel alone in previously treated 
patients with advanced gastric cancers [6]. The current 
study was conducted to primarily support the use of ramu-
cirumab in combination with paclitaxel for treatment in 
this patient population. Other studies have demonstrated 
that ramucirumab significantly improved overall survival 
as monotherapy; in combination with docetaxel; or in com-
bination with irinotecan, folinic acid, and 5-fluorouracil 
(FOLFIRI) as second-line therapy in gastric, NSCLC, and 
metastatic colorectal cancer, respectively [5, 18, 19]. Two 
phase II studies evaluating the effect of concomitant ramu-
cirumab on the pharmacokinetics of docetaxel or FOLFIRI 
in patients with advanced malignant solid tumors demon-
strated no DDI between ramucirumab and these agents [20, 
21].
The principal hematologic toxicity associated with 
paclitaxel is neutropenia [9]. In the RAINBOW trial, the 
incidence of grade 3 or 4 neutropenia was higher in the 
ramucirumab/paclitaxel group (grade 3, 71 patients [22 %]; 
grade 4, 62 patients [19 %]) versus the placebo/paclitaxel 
group (grade 3, 51 patients [16 %]; grade 4, 11 patients 
[3 %]) [6]. In this study, grade ≥3 neutropenia occurred 
in 3 patients (12.5 %) in Part A, and no patients in Part B. 
Results from this current study suggest that a synergistic 
effect of ramucirumab on paclitaxel-induced neutropenia is 
unlikely due to pharmacokinetic interactions.
No unexpected TEAEs or SAEs were observed with 
ramucirumab monotherapy or in combination with pacli-
taxel. The incidence and severity of TEAEs were consist-
ent with the known safety profiles of paclitaxel and ramu-
cirumab. Thus, these results demonstrate that no starting 
dose adjustments are needed for ramucirumab when coad-
ministered with paclitaxel 80 mg/m2, and no starting dose 
Table 5  Treatment-emergent adverse events occurring in at least 
10 % of patients









Fatigue 12 (50) 0 2 (13) 1 (6)
Anemia 10 (42) 1 (4) 0 0
Diarrhea 7 (29) 0 2 (13) 0
Decreased appetite 7 (29) 1 (4) 0 0
Epistaxis 7 (29) 0 4 (25) 0
Alopecia 6 (25) 0 0 0
Constipation 6 (25) 0 0 0
Nausea 6 (25) 0 3 (19) 0
Dizziness 5 (21) 0 0 0
Dyspnea 5 (21) 0 0 0
Headache 5 (21) 0 2 (13) 0
Hypertension 5 (21) 2 (8) 0 0
Pyrexia 5 (21) 0 0 0
Abdominal pain 4 (17) 0 2 (13) 0
Back pain 4 (17) 2 (8) 0 0
Cough 4 (17) 1 (4) 0 0
Dysgeusia 4 (17) 0 0 0
Myalgia 4 (17) 0 0 0
Neuropathy periph-
eral
4 (17) 0 0 0
Neutropenia 4 (17) 3 (13) 0 0
Edema peripheral 4 (17) 0 0 0
Upper respiratory 
tract infection
4 (17) 0 0 0
Vomiting 4 (17) 0 0 0
Arthralgia 3 (13) 0 0 0
Dry skin 3 (13) 0 0 0
Flushing 3 (13) 0 0 0
Infusion-related 
reaction
3 (13) 0 0 0
Pruritus 3 (13) 0 0 0
Stomatitis 3 (13) 0 2 (13) 0
Vision blurred 3 (13) 0 0 0
Weight decreased 3 (13) 0 0 0
Hyperglycemia 0 0 2 (13) 0
Insomnia 0 0 3 (19) 0
Decreased appetite 0 0 2 (13) 0
Dry mouth 0 0 2 (13) 0
Musculoskeletal 
pain
0 0 2 (13) 0
Stomatitis 0 0 2 (13) 0
Urinary tract infec-
tion
0 0 2 (13) 0
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adjustments are needed for paclitaxel when coadministered 
with ramucirumab 8 mg/kg, due to concerns for DDIs.
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